| Characteristic . | Total population (N = 323) . |
|---|---|
| Age, mean (SD), years | 47.2 (9.31) |
| Sex, n (%) | |
| Female | 190 (58.8) |
| Male | 133 (41.2) |
| Race, n (%) | |
| Asian | 0 |
| Black or African American | 6 (1.9) |
| Caucasian | 312 (96.6) |
| Mixed | 1 (0.3) |
| Not collected | 4 (1.2) |
| Height, mean (SD), cm | 169.6 (8.94) |
| Weight, mean (SD), kg | 71.7 (15.70) |
| Body mass index, mean (SD), kg/m2 | 24.8 (4.80) |
| MS subtype, n (%) | |
| Relapsing–remitting | 205 (64.7)a |
| Primary progressive | 17 (5.4)a |
| Secondary progressive | 95 (30.0)a |
| TNmAS-MAL score, mean (SD) | 6.3 (3.25) |
| Prior therapy, n (%) | |
| Baclofen | 11 (3.4) |
| Diazepam | 0 |
| Gabapentin | 1 (0.3) |
| Tizanidine | 0 |
| Characteristic . | Total population (N = 323) . |
|---|---|
| Age, mean (SD), years | 47.2 (9.31) |
| Sex, n (%) | |
| Female | 190 (58.8) |
| Male | 133 (41.2) |
| Race, n (%) | |
| Asian | 0 |
| Black or African American | 6 (1.9) |
| Caucasian | 312 (96.6) |
| Mixed | 1 (0.3) |
| Not collected | 4 (1.2) |
| Height, mean (SD), cm | 169.6 (8.94) |
| Weight, mean (SD), kg | 71.7 (15.70) |
| Body mass index, mean (SD), kg/m2 | 24.8 (4.80) |
| MS subtype, n (%) | |
| Relapsing–remitting | 205 (64.7)a |
| Primary progressive | 17 (5.4)a |
| Secondary progressive | 95 (30.0)a |
| TNmAS-MAL score, mean (SD) | 6.3 (3.25) |
| Prior therapy, n (%) | |
| Baclofen | 11 (3.4) |
| Diazepam | 0 |
| Gabapentin | 1 (0.3) |
| Tizanidine | 0 |
MS subtype was not recorded for the six de novo subjects. MS, multiple sclerosis; SD, standard deviation; TNmAS-MAL, Total Numeric-transformed Modified Ashworth Scale-most affected limb.
| Characteristic . | Total population (N = 323) . |
|---|---|
| Age, mean (SD), years | 47.2 (9.31) |
| Sex, n (%) | |
| Female | 190 (58.8) |
| Male | 133 (41.2) |
| Race, n (%) | |
| Asian | 0 |
| Black or African American | 6 (1.9) |
| Caucasian | 312 (96.6) |
| Mixed | 1 (0.3) |
| Not collected | 4 (1.2) |
| Height, mean (SD), cm | 169.6 (8.94) |
| Weight, mean (SD), kg | 71.7 (15.70) |
| Body mass index, mean (SD), kg/m2 | 24.8 (4.80) |
| MS subtype, n (%) | |
| Relapsing–remitting | 205 (64.7)a |
| Primary progressive | 17 (5.4)a |
| Secondary progressive | 95 (30.0)a |
| TNmAS-MAL score, mean (SD) | 6.3 (3.25) |
| Prior therapy, n (%) | |
| Baclofen | 11 (3.4) |
| Diazepam | 0 |
| Gabapentin | 1 (0.3) |
| Tizanidine | 0 |
| Characteristic . | Total population (N = 323) . |
|---|---|
| Age, mean (SD), years | 47.2 (9.31) |
| Sex, n (%) | |
| Female | 190 (58.8) |
| Male | 133 (41.2) |
| Race, n (%) | |
| Asian | 0 |
| Black or African American | 6 (1.9) |
| Caucasian | 312 (96.6) |
| Mixed | 1 (0.3) |
| Not collected | 4 (1.2) |
| Height, mean (SD), cm | 169.6 (8.94) |
| Weight, mean (SD), kg | 71.7 (15.70) |
| Body mass index, mean (SD), kg/m2 | 24.8 (4.80) |
| MS subtype, n (%) | |
| Relapsing–remitting | 205 (64.7)a |
| Primary progressive | 17 (5.4)a |
| Secondary progressive | 95 (30.0)a |
| TNmAS-MAL score, mean (SD) | 6.3 (3.25) |
| Prior therapy, n (%) | |
| Baclofen | 11 (3.4) |
| Diazepam | 0 |
| Gabapentin | 1 (0.3) |
| Tizanidine | 0 |
MS subtype was not recorded for the six de novo subjects. MS, multiple sclerosis; SD, standard deviation; TNmAS-MAL, Total Numeric-transformed Modified Ashworth Scale-most affected limb.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
